×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TGTX – tg therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TGTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/1
04:40 am
tgtx
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]
Low
Report
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 [Yahoo! Finance]
2/28
07:02 pm
tgtx
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
Low
Report
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation [Yahoo! Finance]
2/27
09:16 am
tgtx
TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
TG Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:37 pm
tgtx
TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Low
Report
TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
2/26
02:17 pm
tgtx
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
Low
Report
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript [Yahoo! Finance]
2/26
12:37 pm
tgtx
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]
Neutral
Report
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program [Seeking Alpha]
2/26
07:32 am
tgtx
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance [Yahoo! Finance]
High
Report
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance [Yahoo! Finance]
2/26
07:00 am
tgtx
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Medium
Report
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/27
05:05 pm
tgtx
Form 10-K TG THERAPEUTICS, INC. For: Dec 31
Low
Report
Form 10-K TG THERAPEUTICS, INC. For: Dec 31
2/26
07:08 am
tgtx
Form 8-K TG THERAPEUTICS, INC. For: Feb 26
High
Report
Form 8-K TG THERAPEUTICS, INC. For: Feb 26
1/29
05:25 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 28 Filed by: Charney Laurence N
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 28 Filed by: Charney Laurence N
1/13
04:28 pm
tgtx
Form 8-K TG THERAPEUTICS, INC. For: Jan 13
Medium
Report
Form 8-K TG THERAPEUTICS, INC. For: Jan 13
1/9
05:16 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: WEISS MICHAEL S
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: WEISS MICHAEL S
1/9
05:15 pm
tgtx
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: Power Sean A
Low
Report
Form 4 TG THERAPEUTICS, INC. For: Jan 08 Filed by: Power Sean A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/8
TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition
24.6%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
12/23 TG Therapeutics Announces $50.0 Million Registered Direct Public Offering of Common Stock to a Single Institutional Investor 15.9%
6/26 TG Therapeutics: Hitting A Growth Inflection [Seeking Alpha] 14.3%
10/28 TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma 13.2%
4/18 TG Therapeutics Inc (NASDAQ: TGTX) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $25.00 price target on the stock. 8.9%
6/18 TG Therapeutics to Present at the Raymond James Life Sciences and MedTech Conference 7.5%
3/20 Form 424B5 TG THERAPEUTICS, INC. 7.3%
4/17 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 6.5%
8/29 TG Therapeutics Announces Data Presentations at the Upcoming 35th Annual Congress of ECTRIMS 5.4%
11/8 TG Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results and Business Update 5.1%
TOP News Decliners
3/14
TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
-16.5%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
3/7 TG Therapeutics Inc (NASDAQ: TGTX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -15.1%
5/10 Form 10-Q TG THERAPEUTICS, INC. For: May 10 -9.4%
12/6 TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Exposition -8.5%
5/7 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting -8.0%
8/22 TG Therapeutics Inc (NASDAQ: TGTX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.2%
5/10 Q1/2019 3/31/2019 EPS -0.430 ZacksConsensus -0.470 ActVsEst 0.040 - Beat -6.8%
1/17 TG Therapeutics Inc (NASDAQ: TGTX) had its price target raised by analysts at HC Wainwright from $20.00 to $24.00. They now have a "buy" rating on the stock. -5.8%
9/5 Form S-3ASR TG THERAPEUTICS, INC. -5.7%
9/20 TG Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: